Luca Bertamini

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Luca Bertamini, Stefania Oliva, Delia Rota‐Scalabrini et al. · Journal of Clinical Oncology · 2022 · 88 citations · Full text

Medicine, Hematology, Oncology +17

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

Roberto Mina, Pellegrino Musto, Delia Rota‐Scalabrini et al. · The Lancet Oncology · 2022 · 85 citations · Full text

Medicine, Hematology, Oncology +17

Whole-genome sequencing analysis of semi-supercentenarians

Paolo Garagnani, Julien Marquis, Massimo Delledonne et al. · eLife · 2021 · 74 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial

Francesca Gay, Pellegrino Musto, Delia Rota Scalabrini et al. · Blood · 2020 · 44 citations

Medicine, Oncology, Stem Cell Transplantation +10

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

Elena Zamagni, Stefania Oliva, Francesca Gay et al. · EClinicalMedicine · 2023 · 34 citations · Full text

Medicine, Nuclear Medicine, Radiology +17